Privately-held Ambys Medicines has announced that it has opened a 52,000-ft² facility dedicated to hepatocyte manufacturing. The facility is certified to current Good Manufacturing Practices (cGMP) regulations. The company, based in South San Francisco, California, also presented data on its novel bioreactor manufacturing at the Joint Congress of the International Xenotransplantation Association, IXA-CTRMS-2021. Focused on…
Noninvasive liver exam plays role in fighting viral hepatitis and fatty liver disease
Millions of Americans who are living with hepatitis C virus (HCV) will develop a chronic infection that, if left untreated, can cause serious health problems, including liver disease, cirrhosis, liver failure and liver cancer. More than one-third of HCV-infected individuals progress to advanced fibrosis and cirrhosis, and among those with cirrhosis, about 3–5% per year…